285 related articles for article (PubMed ID: 10652432)
1. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
2. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice.
Carmon L; Bobilev-Priel I; Brenner B; Bobilev D; Paz A; Bar-Haim E; Tirosh B; Klein T; Fridkin M; Lemonnier F; Tzehoval E; Eisenbach L
J Clin Invest; 2002 Aug; 110(4):453-62. PubMed ID: 12189239
[TBL] [Abstract][Full Text] [Related]
3. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
4. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
[TBL] [Abstract][Full Text] [Related]
5. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
[TBL] [Abstract][Full Text] [Related]
6. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.
Pascolo S; Bervas N; Ure JM; Smith AG; Lemonnier FA; Pérarnau B
J Exp Med; 1997 Jun; 185(12):2043-51. PubMed ID: 9182675
[TBL] [Abstract][Full Text] [Related]
7. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
[TBL] [Abstract][Full Text] [Related]
8. CTL in mice immunized with human mucin 1 are MHC-restricted.
Apostolopoulos V; Loveland BE; Pietersz GA; McKenzie IF
J Immunol; 1995 Dec; 155(11):5089-94. PubMed ID: 7594517
[TBL] [Abstract][Full Text] [Related]
9. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
Uger RA; Barber BH
J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
11. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
Alexander J; Oseroff C; Sidney J; Sette A
Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based vaccines in patients with hematological malignancies.
Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
14. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
Firat H; Garcia-Pons F; Tourdot S; Pascolo S; Scardino A; Garcia Z; Michel ML; Jack RW; Jung G; Kosmatopoulos K; Mateo L; Suhrbier A; Lemonnier FA; Langlade-Demoyen P
Eur J Immunol; 1999 Oct; 29(10):3112-21. PubMed ID: 10540322
[TBL] [Abstract][Full Text] [Related]
15. Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes.
Alexander J; Oseroff C; Sidney J; Wentworth P; Keogh E; Hermanson G; Chisari FV; Kubo RT; Grey HM; Sette A
J Immunol; 1997 Nov; 159(10):4753-61. PubMed ID: 9366399
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.
Barra C; Pérarnau B; Gerlinger P; Lemeur M; Gillet A; Gibier P; Lemonnier FA
J Immunol; 1989 Nov; 143(10):3117-24. PubMed ID: 2478616
[TBL] [Abstract][Full Text] [Related]
17. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
19. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
[TBL] [Abstract][Full Text] [Related]
20. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
